Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 2
1983 7
1984 11
1985 11
1986 6
1987 7
1988 6
1989 16
1990 19
1991 28
1992 40
1993 29
1994 25
1995 18
1996 17
1997 20
1998 21
1999 25
2000 24
2001 24
2002 13
2003 19
2004 27
2005 15
2006 20
2007 24
2008 21
2009 23
2010 19
2011 20
2012 21
2013 21
2014 20
2015 28
2016 27
2017 13
2018 23
2019 17
2020 63
2021 86
2022 81
2023 47
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

960 results

Results by year

Filters applied: . Clear all
Page 1
Anticoagulation with nafamostat mesilate during extracorporeal life support.
Lang Y, Zheng Y, Qi B, Zheng W, Wei J, Zhao C, Gao W, Li T. Lang Y, et al. Int J Cardiol. 2022 Nov 1;366:71-79. doi: 10.1016/j.ijcard.2022.07.022. Epub 2022 Jul 16. Int J Cardiol. 2022. PMID: 35850387 Review.
Nafamostat mesylate (NM) affects coagulation and fibrinolysis and impedes obesity-associated protein demethylase activity, which regulates Na(+)/K(+) transport properties and the NF-kappaB signaling pathway. ...
Nafamostat mesylate (NM) affects coagulation and fibrinolysis and impedes obesity-associated protein demethylase activity, which regu …
Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: A systematic review.
Sanfilippo F, Currò JM, La Via L, Dezio V, Martucci G, Brancati S, Murabito P, Pappalardo F, Astuto M. Sanfilippo F, et al. Artif Organs. 2022 Dec;46(12):2371-2381. doi: 10.1111/aor.14276. Epub 2022 May 9. Artif Organs. 2022. PMID: 35531906 Review.
However, patients with bleeding risk and/or heparin-related side effects may necessitate alternative strategies: among these, nafamostat mesilate (NM) has been reported. METHODS: We conducted a systematic literature search (PubMed and EMBASE, updated 12/08/2021), in …
However, patients with bleeding risk and/or heparin-related side effects may necessitate alternative strategies: among these, nafamostat …
Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation.
Chen P, Zhao LJ, Huang L, He WQ, Tang YR, Liu Y, Ren JD. Chen P, et al. Inflamm Res. 2023 Sep;72(9):1919-1932. doi: 10.1007/s00011-023-01794-0. Epub 2023 Sep 19. Inflamm Res. 2023. PMID: 37725105
OBJECTIVE: Nafamostat mesilate (NM), a synthetic broad-spectrum serine protease inhibitor, has been commonly used for treating acute pancreatitis (AP) and other inflammatory-associated diseases in some East Asia countries. ...
OBJECTIVE: Nafamostat mesilate (NM), a synthetic broad-spectrum serine protease inhibitor, has been commonly used for treating …
Nafamostat mesilate inhibits linezolid metabolism via its antioxidant effects.
Kuriyama N, Matsumoto K, Morita K, Shimomura Y, Hara Y, Hasegawa D, Nakamura T, Yamashita C, Kato Y, Komura H, Nishida O. Kuriyama N, et al. Ther Apher Dial. 2020 Oct;24(5):499-502. doi: 10.1111/1744-9987.13545. Epub 2020 Aug 4. Ther Apher Dial. 2020. PMID: 32524735
Patients who undergo renal replacement therapy often exhibit a high plasma linezolid concentration. Linezolid is metabolized via oxidation. Nafamostat mesilate has antioxidant effects and is frequently used as an anticoagulant during renal replacement therapy. We ai …
Patients who undergo renal replacement therapy often exhibit a high plasma linezolid concentration. Linezolid is metabolized via oxidation. …
The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis.
Kim JS, Lee SH, Park N, Huh G, Chun JW, Choi JH, Cho IR, Paik WH, Ryu JK, Kim YT. Kim JS, et al. BMC Gastroenterol. 2022 May 31;22(1):271. doi: 10.1186/s12876-022-02345-3. BMC Gastroenterol. 2022. PMID: 35641898 Free PMC article.
However, no studies have administered nafamostat mesilate after ERCP. So we investigated if the infusion of nafamostat mesilate after ERCP can affect the post-ERCP pancreatitis (PEP) in high-risk patients. ...Among the PEP patients, mild PEP was signif …
However, no studies have administered nafamostat mesilate after ERCP. So we investigated if the infusion of nafamostat …
Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials.
Xie Y, Cheng Z, Deng C, Deng M, Zhang H. Xie Y, et al. Medicine (Baltimore). 2023 Oct 13;102(41):e35174. doi: 10.1097/MD.0000000000035174. Medicine (Baltimore). 2023. PMID: 37832051 Free PMC article.
OBJECTIVES: To evaluate the efficacy of nafamostat mesilate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) by conduct a systematic review and meta-analysis. METHOD: We retrieved for all randomized controlled trials (RCTs) …
OBJECTIVES: To evaluate the efficacy of nafamostat mesilate in the prevention of post-endoscopic retrograde cholangiopancreato …
Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial.
Okugawa S, Ikeda M, Kashiwabara K, Moritoyo T, Kohsaka T, Shimizu T, Hagiya H, Hasegawa K, Otsuka F, Miwa A, Kisimoto N, Mizoguchi A, Imamura A, Ikeuchi K, Tsutsumi T, Jubishi D, Hashimoto H, Okamoto K, Harada S, Inoue JI, Seto Y, Moriya K. Okugawa S, et al. Int J Antimicrob Agents. 2023 Sep;62(3):106922. doi: 10.1016/j.ijantimicag.2023.106922. Epub 2023 Jul 8. Int J Antimicrob Agents. 2023. PMID: 37429450 Free article. Clinical Trial.
The primary endpoint was area under the curve for decrease in SARS-CoV-2 viral load in nasopharyngeal samples from baseline to day 6. RESULTS: Of the 30 randomized patients, 19 received nafamostat. Overall, 10 patients received low-dose nafamostat, 9 patients receiv …
The primary endpoint was area under the curve for decrease in SARS-CoV-2 viral load in nasopharyngeal samples from baseline to day 6. RESULT …
Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.
Uwagawa T, Sakamoto T, Gocho T, Shiba H, Onda S, Yasuda J, Shirai Y, Hamura R, Furukawa K, Yanaga K, Ikegami T. Uwagawa T, et al. PLoS One. 2022 May 11;17(5):e0267623. doi: 10.1371/journal.pone.0267623. eCollection 2022. PLoS One. 2022. PMID: 35544539 Free PMC article. Clinical Trial.
PURPOSE: To assess the efficacy of combination chemotherapy with nafamostat mesilate, gemcitabine and S-1 for unresectable pancreatic cancer patients. ...
PURPOSE: To assess the efficacy of combination chemotherapy with nafamostat mesilate, gemcitabine and S-1 for unresectable pan …
Nafamostat Mesilate Attenuates Ischemia-Reperfusion-Induced Renal Injury.
Na KR, Choi H, Jeong JY, Lee KW, Chang YK, Choi DE. Na KR, et al. Transplant Proc. 2016 Jul-Aug;48(6):2192-9. doi: 10.1016/j.transproceed.2016.03.050. Transplant Proc. 2016. PMID: 27569970
BACKGROUND: It has been reported that nafamostat mesilate (NM) inhibits inflammatory injury via inhibition of complement activation in ischemic heart, liver, and intestine. ...
BACKGROUND: It has been reported that nafamostat mesilate (NM) inhibits inflammatory injury via inhibition of complement activ …
Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY. Hwang SD, et al. Int J Artif Organs. 2013 Mar;36(3):208-16. doi: 10.5301/IJAO.5000191. Epub 2013 Feb 13. Int J Artif Organs. 2013. PMID: 23404639
In Cox proportional hazard models, nafamostat mesilate predicted longer filter survival. Although nafamostat mesilate induced activated partial thromboplastin time prolongation in 11 circuits (5.4%), bleeding episodes were not increased. CONCLUSIONS: …
In Cox proportional hazard models, nafamostat mesilate predicted longer filter survival. Although nafamostat mesilat …
960 results

Searches related to "nafamostat mesilate"